Investigational New Drugs 1992-Nov
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Palavras-chave
Resumo
Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.